Novavax News

Dallas, TX - C.R. Bard, Inc. went down 6.74% to close at $78.49 on 6.45 million shares after Piper Jaffray downgraded C.R. Bard from Neutral to Underweight and the price target was lowered from $84 to $71. C. R. Bard, Inc.

The H1N1 influenza strain, also commonly referred to as the swine flu, has been in the headlines most of this year.

Shares of Select Comfort Corp. climbed Tuesday as the mattress maker announced plans to lower its debt and bolster working capital by selling some shares.

Plug Power Inc., a developer of energy technology, said Wednesday that Nasdaq has notified the company it has violated a rule that requires its share price not to close at a value of less than $1 for 30 days in a row.

Biotech drug developer Novavax Inc. said Wednesday it closed a public offering for 6.8 million shares of common stock.

Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.

Several stocks trading under $5 were poised to move on above-average volume during Tuesday's session.

Several stocks trading under $5 were poised to move on above-average volume during Monday's session.

Novavax, Inc. reported favorable initial results from the first stage of a two-stage pivotal Phase II study evaluating the safety and immunogenicity of the company's 2009 H1N1 virus-like particle pandemic influenza vaccine.

Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.

Stock futures were holding steady for most of the morning, but headed positive as analysts evaluate early holiday retail sales ahead of Cyber Monday.

Drug stocks were split Monday as shares of Theravance Inc. slid on news that U.S. regulators have refused to approve its pneumonia treatment telavancin until they receive more supporting information on the product.

Biotechnology company Novavax announced it priced a public offering of 6.8 million common shares, at 3 dollars and 30 cents each.

Several stocks trading near $5 were poised to move on above-average volume during Friday's session.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/11/09, Covidien will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York on Wednesday, November 18, 2009.

That's a pitch I'm sure you've heard some semblance of at cocktail parties, golf outings, weddings, and, of course, on the Internet.

Several small-cap stocks were poised to move on above-average volume during Friday's session Novavax slipped by 3 cents, or 0.7%, to $4 after the company reported a third-quarter loss of 8 cents a share, a penny better than the Thomson Reuters average estimate.

While Novavax moves closer to commercializing its flu vaccines, it continues to lose money.

On this day, we have begun tracking the following companies as they have shown remarkable correction in recent days, you can access these free reports with a number of other reviews by signing up for your complimentary membership at: Penn West Energy Trust - Sector: Basic Materials Gerdau AmeriSteel Corp.

Stock-PR.com, a division of Crown Equity Holdings Inc. tracks stocks daily and is pleased to offer its hot stock alerts.